Radiotherapy of head-neck cancer is associated with significant side effects. Using daily online adaptive radiotherapy to account for the changing anatomy, radiation to organs at risk can be lowered. We will investigate whether this is feasible and associated with a reduction in the risk of toxicity.
Patients with histologically proven squamous cell carcinoma of the pharynx or larynx planned for primary radiotherapy with curative intent No current or earlier malignancies, which may influence treatment, evaluation or outcome of the head-neck cancer Informed consent as required by law The patient cannot participate in conflicting protocols Stage I-IV (excluding T1-T2N0 carcinoma of the glottic larynx) ECOG/WHO performance status 0-2
None
Single group
Daily online adaptive radiotherapy
RadiationThe patients will undergo daily online adaptive re-optimisation of the radiotherapy treatment plan following daily recontouring.
Risk of dysphagia and xerostomia six months post-treatment assesed by normal-tissue complication probability (NTCP) models
Click on the lead sponsor to view all of their trials.
